This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 10
  • /
  • European Commission approves Mounjaroan adjunct to...
News

European Commission approves Mounjaroan adjunct to diet and exercise for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

Read time: 1 mins
Published:5th Oct 2022

Eli Lilly and Company announced that the European Commission has granted marketing authorisation for the use of Mounjaro (tirzepatide), a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, as an adjunct to diet and exercise for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

The decision follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use’s (CHMP) positive opinion issued in July 2022.

Condition: Diabetes Type 2
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.